OraSure Technologies (OSUR) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
OraSure Announces 2015 Second Quarter Financial Results
August 5, 2015 4:14 PM EDTBETHLEHEM, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2015.
Financial Highlights
Consolidated net revenues for the second quarter of 2015 were a record $30.4 million, a 15% increase from the comparable quarter of 2014. Consolidated net revenues for the six months ended June 30, 2015 were $57.5 million, also a 15% increase from the comparable period of 2014. Â The Company's molecular collection systems subsidiary, DNA Genotek ("DNAG"), contributed $8.1... MoreOrasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
August 3, 2015 6:00 AM EDTBETHLEHEM, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick® Ebola Rapid Antigen Test for use with fingerstick and venous whole blood.
This test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories and facilities adequately equipped, trained, and capable of testing for Ebola infection (including... More
Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
August 3, 2015 6:00 AM EDTBETHLEHEM, Pa., Aug. 3, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick® Ebola Rapid Antigen Test for use with fingerstick and venous whole blood.
This test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories and facilities adequately equipped, trained, and capable of testing for Ebola infection (including... More
